Fairvalue-Calculator Fairvalue-Calculator
EN DE

Nuchev Limited (NUC) Fair Value & Analysis

Consumer Defensive · AU · Market cap A$19.6M

PriceA$0.1000
Fair ValueA$0.0200
Upside-80.0%
Quality95/100
Evidence: Low Range A$0.0100 – A$0.0300

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Nuchev Limited (NUC) currently trades at A$0.1000, while our model-based Fair Value estimate is A$0.0200 — implying the stock looks roughly 80.0% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Nuchev Limited, a health and nutrition solutions company, produces, markets, and sells nutritional and vitamin and dietary supplement products in Australia and China. The company offers goat and bovine milk-based formula and nutritional products under the Oli6 brand. It sells its products through pharmacy, grocery, and other retail channels, as well as e-commerce channels. The company was incorporated in 2013 and is headquartered in Melbourne, Australia.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Nuchev Limited (NUC) undervalued?
As of Jun 26, 2026, our model estimates a fair value of A$0.0200 versus a price of A$0.1000 — about −80% (overvalued). Model-based estimate, not financial advice.
What is the fair value of NUC?
Our 21-model fair value for Nuchev Limited is A$0.0200 (as of Jun 26, 2026), built from audited fundamentals. The current price is A$0.1000.
What is the quality score of NUC?
Nuchev Limited has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.